» Articles » PMID: 17110895

Diabetes Mellitus and Dementia

Overview
Journal Diabetes Metab
Specialty Endocrinology
Date 2006 Nov 18
PMID 17110895
Citations 95
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease (AD) and diabetes mellitus (DM) are two of the most common and devastating health problems in the elderly. They share a number of common features amongst which high prevalence after 65 years, important impact of patient's quality of life, substantial health care costs. Reviews on the epidemiological studies on cognitive impairment in patients with DM found evidence of cross-sectional and prospective associations between type 2 DM and moderate cognitive impairment, on memory and executive functions. There is also evidence for an elevated risk of both vascular dementia and AD in patients with type 2 DM, albeit with strong interaction of other factors such as hypertension, dyslipidaemia and ApoE genotype. DM is an independent predictor of post-stroke dementia. DM being an atherogenic risk factor, it may increase the risk of dementia through associations with stroke, causing vascular dementia. In addition, vascular reactivity may be adversely affected by advanced glycosylation end products resulting in more subtle perfusion abnormalities. Cerebrovascular disease may exacerbate AD through direct interactions between the two pathological processes or through cognitive impairment secondary to cerebrovascular disease "unmasking" AD at an earlier stage than it would otherwise become apparent. The increased risk of AD may also be mediated by the exacerbation of B-amyloid neurotoxicity by advanced glycosylation end products identified in the matrix of neurofibrillary tangles and amyloid plaques in AD brains, or associations with insulin functions. Decreased cholinergic transport across the blood-brain barrier observed in diabetic animals may exacerbate cognitive impairment in AD. Many interventions could reduce the cognitive decline associated with DM, yet not enough are taken into account so far.

Citing Articles

Conquering Insulin Network Dysfunctions in Alzheimer's Disease: Where Are We Today?.

de la Monte S J Alzheimers Dis. 2024; 101(s1):S317-S343.

PMID: 39422949 PMC: 11807374. DOI: 10.3233/JAD-240069.


Recent advances in gold nanostructure-based biosensors in detecting diabetes biomarkers.

Jamshidnejad-Tosaramandani T, Kashanian S, Omidfar K, Schioth H Front Bioeng Biotechnol. 2024; 12:1446355.

PMID: 39355278 PMC: 11442290. DOI: 10.3389/fbioe.2024.1446355.


The individual and combined impacts of pre-existing diabetes and dementia on ischemic stroke outcomes: a registry-based cohort study.

Kyaw K, Pana T, Bettencourt-Silva J, Metcalf A, Myint P, Potter J BMC Cardiovasc Disord. 2024; 24(1):396.

PMID: 39080558 PMC: 11290225. DOI: 10.1186/s12872-024-04050-3.


The clinical features and potential mechanisms of cognitive disorders in peripheral autoimmune and inflammatory diseases.

Fan K, Huang T, Yu J, Li Y, Jin J Fundam Res. 2024; 4(2):226-236.

PMID: 38933510 PMC: 11197673. DOI: 10.1016/j.fmre.2022.12.005.


Incretin Therapy and Insulin Signaling: Therapeutic Targets for Diabetes And Associated Dementia.

Joshi D Curr Diabetes Rev. 2024; 21(4):57-63.

PMID: 38425117 DOI: 10.2174/0115733998279875240216093902.